Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (41-50 of 155) with videos related to

Pageof 16
Sort By:
The Prostate|May 15, 2003
Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivoSamuel R Denmeade, Ivan Litvinov, Lori J Sokoll, et al.
Molecular Cancer Therapeutics|November 21, 2007
A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancerSachin S Chandran, Anjan Nan, D Marc Rosen, et al.
The Oncologist|April 7, 2023
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate CancerSamuel R Denmeade, Laura A Sena, Hao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancersYi Xu, Susan L Dalrymple, Robyn E Becker, et al.
Journal of Medicinal Chemistry|May 23, 2013
Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitorsMaya B Kostova, D Marc Rosen, Ying Chen, et al.
Oncotarget|June 2, 2018
PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancerOliver C Rogers, Lizamma Anthony, D Marc Rosen, et al.
The Prostate|February 3, 2016
Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategyEmmanuel S Akinboye, W Nathaniel Brennen, D Marc Rosen, et al.
The Prostate|May 7, 2019
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302Benjamin A Teply, Fang Qiu, Emmanuel S Antonarakis, et al.
Journal of Medicinal Chemistry|August 8, 2012
Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancerEmmanuel S Akinboye, Marc D Rosen, Samuel R Denmeade, et al.
European Urology|December 7, 2010
Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasiaSamuel R Denmeade, Blair Egerdie, Gary Steinhoff, et al.
Pageof 16

Showing results (41-50 of 155) with videos related to

Sort By:
Pageof 16
The Prostate|May 15, 2003
Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivoSamuel R Denmeade, Ivan Litvinov, Lori J Sokoll, et al.
Molecular Cancer Therapeutics|November 21, 2007
A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancerSachin S Chandran, Anjan Nan, D Marc Rosen, et al.
The Oncologist|April 7, 2023
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate CancerSamuel R Denmeade, Laura A Sena, Hao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancersYi Xu, Susan L Dalrymple, Robyn E Becker, et al.
Journal of Medicinal Chemistry|May 23, 2013
Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitorsMaya B Kostova, D Marc Rosen, Ying Chen, et al.
Oncotarget|June 2, 2018
PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancerOliver C Rogers, Lizamma Anthony, D Marc Rosen, et al.
The Prostate|February 3, 2016
Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategyEmmanuel S Akinboye, W Nathaniel Brennen, D Marc Rosen, et al.
The Prostate|May 7, 2019
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302Benjamin A Teply, Fang Qiu, Emmanuel S Antonarakis, et al.
Journal of Medicinal Chemistry|August 8, 2012
Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancerEmmanuel S Akinboye, Marc D Rosen, Samuel R Denmeade, et al.
European Urology|December 7, 2010
Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasiaSamuel R Denmeade, Blair Egerdie, Gary Steinhoff, et al.
Pageof 16